financetom
Business
financetom
/
Business
/
Regenxbio Plans to Sell $125 Million in Equity Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Regenxbio Plans to Sell $125 Million in Equity Offering
Mar 6, 2024 2:03 PM

04:43 PM EST, 03/06/2024 (MT Newswires) -- Regenxbio ( RGNX ) plans to sell $125 million in common stock in an underwritten public offering.

The company said late Wednesday it intends to grant underwriters a 30-day option to purchase up to 15% of the stock sold in the offering as additional shares.

Shares of the company fell 3.1% in after-hours activity.

Price: 23.25, Change: -0.75, Percent Change: -3.13

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
Jan 13, 2025
BAKU, Jan 13 (Reuters) - BP is working to resolve technical problems at the Shah Deniz Alfa (SDA) platform and hopes to resume normal operations as soon as possible, the company told Reuters on Monday. BP suspended work of the platform on Friday after detecting a technical issue at the subsea gas condensate export line between the platform and the...
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Jan 13, 2025
04:39 AM EST, 01/13/2025 (MT Newswires) -- Illumina ( ILMN ) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson ( JNJ ) , and Novartis ( NVS ) . Under the collaboration, deCODE Genetics will process the samples from the UK...
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Jan 13, 2025
04:32 AM EST, 01/13/2025 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) Teva Pharmaceuticals International subsidiary said Monday it has entered into a collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea, in Israel and Europe, excluding Italy. Financial terms were not disclosed. Klinge has licensed the exclusive global commercialization rights...
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Jan 13, 2025
04:47 AM EST, 01/13/2025 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus. Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved